Comparative Pharmacology
Head-to-head clinical analysis: KLOR CON M20 versus SLOW K.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KLOR CON M20 versus SLOW K.
KLOR-CON M20 vs SLOW-K
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Potassium is the major intracellular cation; it is essential for the maintenance of intracellular tonicity, transmission of nerve impulses, contraction of cardiac, skeletal, and smooth muscle, and maintenance of acid-base balance. Potassium replacement therapy corrects hypokalemia.
Potassium is the major intracellular cation; essential for maintenance of intracellular tonicity, transmission of nerve impulses, contraction of cardiac, skeletal, and smooth muscle, and maintenance of normal renal function.
20 mEq potassium chloride orally once daily, adjusted based on serum potassium levels and patient response. Maximum rate of administration: 20 mEq per hour if intravenous; oral doses divided if >20 mEq per dose.
Adults: 600-2400 mg potassium chloride (8-32 mmol K+) orally per day in divided doses, usually 1-2 tablets twice daily. Maximum single dose: 20 mmol. Route: oral. Frequency: 1-4 times daily.
None Documented
None Documented
The terminal elimination half-life of potassium is approximately 8-12 hours in healthy individuals, but is prolonged in renal impairment.
Not applicable; potassium is an electrolyte with no defined elimination half-life; distribution half-life ~2-4 hours
Potassium is primarily excreted renally (approximately 90%) as potassium ion in urine. A small amount is excreted in feces (about 10%).
Primarily renal (>90%) as potassium ions; minimal biliary/fecal elimination (<5%)
Category C
Category C
Potassium Supplement
Potassium Supplement